山东绿叶制药有限公司 Lvye Mediaroom

Luye Pharma's Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao

Reshaping the landscape for the second-line treatments of Small Cell Lung Cancer HONG KONG and MACA...

2024-03-07 10:11 2001

Luye Pharma's Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao

Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea

YANTAI, China, Feb. 5, 2024 /PRNewswire/ -- Luye Pharma Group has entered into an agreement with My...

2024-02-05 18:53 1699

Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea

Boan Biotech's Biologics License Application for Boyounuo® (Bevacizumab Injection) Accepted in Brazil

YANTAI, China, April 11, 2023 /PRNewswire/ -- Boan Biotech today announced that Brazil's Agência Na...

2023-04-11 20:19 2663

Luye Pharma and Duopharma Reach Strategic Partnership to Expand Accessibility of Cholesterol Management Products in Malaysia

KUALA LUMPUR, Malaysia, April 5, 2023 /PRNewswire/ -- Luye Pharma Group (Luye Pharma), an internati...

2023-04-05 10:44 3291

Luye Pharma and Duopharma Reach Strategic Partnership to Expand Accessibility of Cholesterol Management Products in Malaysia

Boan Biotech Announces 2022 Financial Results

Showing accelerated innovation and strong 225% revenue growth YANTAI, China, March 27, 2023 /PRNews...

2023-03-27 23:15 3002

BLA Accepted in China for Boan Biotech's Denosumab Injection (BA1102) for the Oncology Indications

YANTAI, China, March 21, 2023 /PRNewswire/ -- Luye Pharma Group today announced that the Biologics ...

2023-03-21 13:46 2123

Patient Enrollment Completed for the Phase 3 Trial of Boan Biotech's Aflibercept Intravitreous Injection in China

YANTAI, China, March 13, 2023 /PRNewswire/ -- Luye Pharma Group today announced that patient enroll...

2023-03-13 20:36 2187

Boan Biotech's Investigational Long-acting Anti-IL-4Rα Antibody BA2101 Administered for First Patient in Phase I Clinical Trial

YANTAI, China, Feb. 16, 2023 /PRNewswire/ -- Luye Pharma Group today announced that BA2101, an inve...

2023-02-16 08:15 3187

Boan Biotech's Investigational Anti-CD25 Antibody BA1106 Administered for First Patient in Phase I Clinical Trial

YANTAI, China, Feb. 13, 2023 /PRNewswire/ -- Luye Pharma Group today announced that BA1106, an inve...

2023-02-13 08:39 2660

Luye Pharma's Innovative Anti-Cancer Therapy Lurbinectedin to Benefit "Named Patients" in Hong Kong

HONG KONG, Jan. 9, 2023 /PRNewswire/ -- Luye Pharma Group today announced the launch of the Named P...

2023-01-09 18:57 2779

Luye Pharma's Innovative Anti-Cancer Therapy Lurbinectedin to Benefit

Luye Pharma and DCH Auriga Establish an Exclusive Distribution Partnership and Jointly Launch the "We Care About Mental Health" Initiative

* Luye Pharma has granted DCH Auriga Singapore exclusive distribution and marketing rights for Se...

2022-12-13 12:14 3564

Luye Pharma and DCH Auriga Establish an Exclusive Distribution Partnership and Jointly Launch the

Luye Pharma Enters Local Seroquel® Distribution and Marketing Partnership with ICI Pakistan Limited

"We Care About Mental Health" awareness set to increase across APAC * Luye Pharma has granted IC...

2022-09-27 07:59 2135

Luye Pharma Enters Local Seroquel® Distribution and Marketing Partnership with ICI Pakistan Limited

Luye Pharma Grants Laboratorio LIBRA Exclusive Marketing Rights for Seroquel and Seroquel XR in Chile

SHANGHAI, Feb. 9, 2022 /PRNewswire/ -- Luye Pharma Group announced today that it has entered into a...

2022-02-09 11:57 1730

Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets

CHONGQING, China, Dec. 23, 2021 /PRNewswire/ -- Luye Pharma Group today released the encouraging to...

2021-12-23 16:23 2380

Luye Pharma Grants Zambon Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland

BASEL, Switzerland, Nov. 10, 2021 /PRNewswire/ -- Luye Pharma Group (Luye Pharma) today announced t...

2021-11-10 23:38 2924

Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit

Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally...

2021-09-26 10:12 1850

Luye Pharma Becomes the Marketing Authorization Holder for Seroquel and Seroquel XR in Saudi Arabia

JEDDAH, Saudi Arabia, Sept. 17, 2021 /PRNewswire/ -- Luye Pharma Group has recently been granted of...

2021-09-17 22:16 2002

Luye Pharma Enters Distribution Agreement with Zuellig Pharma for Seroquel and Seroquel XR in Malaysia and Brunei, Strengthening Business Presence in Asia Pacific and Improving Access to Evidence-Based Medical Treatments for Mental Health

SUBANG JAYA, Malaysia, Aug. 2, 2021 /PRNewswire/ -- Luye Pharma Group today announced that it has e...

2021-08-02 10:25 3924

The Third Asia Pacific Psychiatry Symposium Takes Place

SHANGHAI, June 28, 2021 /PRNewswire/ -- The global COVID-19 pandemic poses a serious threat to phys...

2021-06-28 15:51 2245

Boan Biotech Publishes Research Results for CEA/CD3 Bispecific Antibody in Antibody Therapeutics

BOSTON, June 24, 2021 /PRNewswire/ -- Luye Pharma Group's subsidiary Boan Biotech recently publishe...

2021-06-24 14:49 2637

Latest News